New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells

References

• Jin T. Mechanisms underlying proglucagon gene expression. J Endocrinol 2008; 198:17 - 28; http://dx.doi.org/10.1677/JOE-08-0085; PMID: 18577568
   PubMed Web of Science ®Google Scholar
• Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20:876 - 913; http://dx.doi.org/10.1210/er.20.6.876; PMID: 10605628
   PubMed Web of Science ®Google Scholar
• Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004; 53:Suppl 3 S197 - 204; http://dx.doi.org/10.2337/diabetes.53.suppl_3.S197; PMID: 15561911
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49:253 - 60; http://dx.doi.org/10.1007/s00125-005-0107-1; PMID: 16416146
   PubMed Web of Science ®Google Scholar
• Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010; 151:1520 - 31; http://dx.doi.org/10.1210/en.2009-1197; PMID: 20172966
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117:2340 - 50; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.739938; PMID: 18427132
   PubMed Web of Science ®Google Scholar
• Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010; 21:59 - 67; http://dx.doi.org/10.1016/j.tem.2009.11.007; PMID: 20018525
   PubMed Web of Science ®Google Scholar
• Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011; 167:177 - 84; http://dx.doi.org/10.1016/j.regpep.2011.01.003; PMID: 21256872
   PubMed Web of Science ®Google Scholar
• Tomas E, Wood JA, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul Pept 2011; 169:43 - 8; http://dx.doi.org/10.1016/j.regpep.2011.04.006; PMID: 21549160
   PubMed Web of Science ®Google Scholar
• Shao W, Yu Z, Fantus IG, Jin T. Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. Cell Signal 2010; 22:1240 - 6; http://dx.doi.org/10.1016/j.cellsig.2010.04.001; PMID: 20385228
   PubMed Web of Science ®Google Scholar
• Ip W, Chiang YT, Jin T. The involvement of the wnt signaling pathway and TCF7L2 in diabetes mellitus: The current understanding, dispute, and perspective. Cell Biosci 2012; 2:28; http://dx.doi.org/10.1186/2045-3701-2-28; PMID: 22892353
   PubMedGoogle Scholar
• Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008; 283:8723 - 35; http://dx.doi.org/10.1074/jbc.M706105200; PMID: 18216022
   PubMed Web of Science ®Google Scholar
• Shao W, Wang D, Chiang YT, Ip W, Zhu L, Xu F, et al. The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis. Diabetes 2012; In press. http://dx.doi.org/10.2337/db12-0365; PMID: 22966074
   PubMed Web of Science ®Google Scholar
• Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 2008; 22:2383 - 92; http://dx.doi.org/10.1210/me.2008-0135; PMID: 18599616
   PubMed Web of Science ®Google Scholar
• Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008; 51:1771 - 80; http://dx.doi.org/10.1007/s00125-008-1084-y; PMID: 18696049
   PubMed Web of Science ®Google Scholar
• Grant SF. Understanding the elusive mechanism of action of TCF7L2 in metabolism. Diabetes 2012; 61:2657 - 8; http://dx.doi.org/10.2337/db12-0891; PMID: 23093653
   PubMed Web of Science ®Google Scholar
• Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220 - 32; http://dx.doi.org/10.1056/NEJMoa0801869; PMID: 19020324
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187 - 215; http://dx.doi.org/10.1210/er.2011-1052; PMID: 22323472
   PubMed Web of Science ®Google Scholar
• Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005; 128:125 - 34; http://dx.doi.org/10.1016/j.regpep.2004.07.019; PMID: 15780432
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93:7911 - 6; http://dx.doi.org/10.1073/pnas.93.15.7911; PMID: 8755576
   PubMed Web of Science ®Google Scholar
• Thyssen S, Arany E, Hill DJ. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 2006; 147:2346 - 56; http://dx.doi.org/10.1210/en.2005-0396; PMID: 16484329
   PubMed Web of Science ®Google Scholar
• Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995; 58:149 - 56; http://dx.doi.org/10.1016/0167-0115(95)00063-H; PMID: 8577927
   PubMed Web of Science ®Google Scholar
• Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005; 48:1882 - 90; http://dx.doi.org/10.1007/s00125-005-1847-7; PMID: 16025254
   PubMed Web of Science ®Google Scholar
• Davidson EP, Coppey LJ, Dake B, Yorek MA. Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity. J Obes 2011; 2011:9 pages; http://dx.doi.org/10.1155/2011/686952; PMID: 20847891
   PubMedGoogle Scholar
• Liu Z, Stanojevic V, Brindamour LJ, Habener JF. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity. J Endocrinol 2012; 213:143 - 54; http://dx.doi.org/10.1530/JOE-11-0328; PMID: 22414687
   PubMed Web of Science ®Google Scholar
• MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51:Suppl 3 S434 - 42; http://dx.doi.org/10.2337/diabetes.51.2007.S434; PMID: 12475787
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153 - 65; http://dx.doi.org/10.1016/j.cmet.2006.01.004; PMID: 16517403
   PubMed Web of Science ®Google Scholar
• Holz GG 4th, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361:362 - 5; http://dx.doi.org/10.1038/361362a0; PMID: 8381211
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145:2653 - 9; http://dx.doi.org/10.1210/en.2004-0015; PMID: 15044356
   PubMed Web of Science ®Google Scholar
• Kwan EP, Gao X, Leung YM, Gaisano HY. Activation of exchange protein directly activated by cyclic adenosine monophosphate and protein kinase A regulate common and distinct steps in promoting plasma membrane exocytic and granule-to-granule fusions in rat islet beta cells. Pancreas 2007; 35:e45 - 54; http://dx.doi.org/10.1097/mpa.0b013e318073d1c9; PMID: 17895835
   PubMedGoogle Scholar
• Takeda Y, Amano A, Noma A, Nakamura Y, Fujimoto S, Inagaki N. Systems analysis of GLP-1 receptor signaling in pancreatic β-cells. Am J Physiol Cell Physiol 2011; 301:C792 - 803; http://dx.doi.org/10.1152/ajpcell.00057.2011; PMID: 21734192
   PubMedGoogle Scholar
• Seino S, Takahashi H, Fujimoto W, Shibasaki T. Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes Metab 2009; 11:Suppl 4 180 - 8; http://dx.doi.org/10.1111/j.1463-1326.2009.01108.x; PMID: 19817800
   PubMedGoogle Scholar
• Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res 2004; 36:787 - 94; http://dx.doi.org/10.1055/s-2004-826165; PMID: 15655710
   PubMed Web of Science ®Google Scholar
• MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51:Suppl 3 S443 - 7; http://dx.doi.org/10.2337/diabetes.51.2007.S443; PMID: 12475788
   PubMedGoogle Scholar
• Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87:3768 - 73; http://dx.doi.org/10.1210/jc.87.8.3768; PMID: 12161508
   PubMed Web of Science ®Google Scholar
• Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Peñacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003; 204:43 - 50; http://dx.doi.org/10.1016/S0303-7207(03)00146-1; PMID: 12850280
   PubMed Web of Science ®Google Scholar
• Vahl TP, Paty BW, Fuller BD, Prigeon RL, D’Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88:1772 - 9; http://dx.doi.org/10.1210/jc.2002-021479; PMID: 12679472
   PubMed Web of Science ®Google Scholar
• Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008; 16:1501 - 9; http://dx.doi.org/10.1038/oby.2008.229; PMID: 18421270
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955 - 61; http://dx.doi.org/10.1161/01.CIR.0000139339.85840.DD; PMID: 15313949
   PubMed Web of Science ®Google Scholar
• Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; 61:888 - 96; http://dx.doi.org/10.2337/db11-1073; PMID: 22357961
   PubMed Web of Science ®Google Scholar
• Spindel ON, World C, Berk BC. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal 2012; 16:587 - 96; http://dx.doi.org/10.1089/ars.2011.4137; PMID: 21929372
   PubMed Web of Science ®Google Scholar
• Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006; 346:1067 - 74; http://dx.doi.org/10.1016/j.bbrc.2006.06.027; PMID: 16782054
   PubMed Web of Science ®Google Scholar
• Shalev A. Lack of TXNIP protects beta-cells against glucotoxicity. Biochem Soc Trans 2008; 36:963 - 5; http://dx.doi.org/10.1042/BST0360963; PMID: 18793170
   PubMed Web of Science ®Google Scholar
• Masson E, Koren S, Razik F, Goldberg H, Kwan EP, Sheu L, et al. High beta-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice. Am J Physiol Endocrinol Metab 2009; 296:E1251 - 61; http://dx.doi.org/10.1152/ajpendo.90619.2008; PMID: 19223654
   PubMedGoogle Scholar
• Corbett JA. Thioredoxin-interacting protein is killing my beta-cells!. Diabetes 2008; 57:797 - 8; http://dx.doi.org/10.2337/db08-0055; PMID: 18375442
   PubMed Web of Science ®Google Scholar
• Chen J, Hui ST, Couto FM, Mungrue IN, Davis DB, Attie AD, et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 2008; 22:3581 - 94; http://dx.doi.org/10.1096/fj.08-111690; PMID: 18552236
   PubMed Web of Science ®Google Scholar
• Jin T, George Fantus I, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 2008; 20:1697 - 704; http://dx.doi.org/10.1016/j.cellsig.2008.04.014; PMID: 18555664
   PubMed Web of Science ®Google Scholar
• Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6:1664 - 8; http://dx.doi.org/10.1016/S0960-9822(02)70790-2; PMID: 8994831
   PubMed Web of Science ®Google Scholar
• Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T. Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem 2003; 278:1380 - 7; http://dx.doi.org/10.1074/jbc.M206006200; PMID: 12421827
   PubMed Web of Science ®Google Scholar
• Chiang YA, Shao W, Xu XX, Chernoff J, Jin T. P21-Activated Protein Kinase 1 (Pak1) Mediates the Cross Talk between Insulin and beta-Catenin on Proglucagon Gene Expression and Its Ablation Affects Glucose Homeostasis in Male C57BL/6 Mice. Endocrinology 2013; 154:77 - 88; http://dx.doi.org/10.1210/en.2012-1781; PMID: 23183186
   PubMed Web of Science ®Google Scholar
• Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280:1457 - 64; http://dx.doi.org/10.1074/jbc.M411487200; PMID: 15525634
   PubMed Web of Science ®Google Scholar
• Fürstenau U, Schwaninger M, Blume R, Jendrusch EM, Knepel W. Characterization of a novel calcium response element in the glucagon gene. J Biol Chem 1999; 274:5851 - 60; http://dx.doi.org/10.1074/jbc.274.9.5851; PMID: 10026208
   PubMed Web of Science ®Google Scholar
• García-Martínez JM, Chocarro-Calvo A, Moya CM, García-Jiménez C. WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 2009; 52:1913 - 24; http://dx.doi.org/10.1007/s00125-009-1429-1; PMID: 19582394
   PubMed Web of Science ®Google Scholar
• Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 2008; 149:2341 - 51; http://dx.doi.org/10.1210/en.2007-1142; PMID: 18258680
   PubMed Web of Science ®Google Scholar
• Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005; 25:9063 - 72; http://dx.doi.org/10.1128/MCB.25.20.9063-9072.2005; PMID: 16199882
   PubMed Web of Science ®Google Scholar
• Zhu G, Wang Y, Huang B, Liang J, Ding Y, Xu A, et al. A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene 2012; 31:1001 - 12; http://dx.doi.org/10.1038/onc.2011.294; PMID: 21822311
   PubMed Web of Science ®Google Scholar
• Ip W, Shao W, Chiang YT, Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2012; 303:E1166 - 76; http://dx.doi.org/10.1152/ajpendo.00249.2012; PMID: 22967502
   PubMedGoogle Scholar
• DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126:4557 - 68; PMID: 10498690
   PubMed Web of Science ®Google Scholar